Proteomik,Genomik, Genetik
(Die deutsche Übersetzung folgt demnächst)
The Max Delbrück Center for Molecular Medicine, the Max Planck
Institute for Molecular Genetics and the Leibniz Institute for
Molecular Pharmacology have been und will be making available a number
of genome and proteomic research technologies available, which will be
instrumental in solving important medical tasks with respect to
neurological disorders like stroke, multiple sclerosis, or epileptic
seizures and may even reveal the cellular networks underlying the
mechanisms of brain damage, brain protection, and regeneration.
- Automated Y2H/Y3H screening technology for the high-throughput identification of human protein-protein interactions; Assays for the systematic validation of interactions; Y2H libraries: 12,000 human prey clones
- Technology for the for the systematic identification of human protein interactions using protein arrays; Spotting robots for the production of protein arrays
- Technology for the isolation and characterization of protein complexes using affinity chromatography and mass spectrometry (Q-Tof Premier; 4000 Q-Trap LC/MS/MS system)
- Array CGH technology (BAC contig and oligonucleotide arrays)
- Illumina Bead Station for high-throughput SNP typing (e.g. homozygosity mapping) and gene expression profiling
- Roche 20 ('454') and Solexa sequencing systems
- Access to large cohorts of patients and families with neurological disorders (e.g. through the Euro-MRX Consortium, our collaboration with Iran and with other partners)
